5040 Cytochrome c oxidase subunit II-like, transmembrane region
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 3 | 5.8 | 0.52× | q = 0.21 | |
| Hydrocarbons | 4 | 0.1 | 48× | not tested | |
| Lipids and lipid-like molecules | 12 | 1.3 | 9.11× | not tested | |
| Organoheterocyclic compounds | 1 | 1.8 | 0.55× | not tested | |
| Organic oxygen compounds | 1 | 2.4 | 0.42× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03429 | CDL | Tetrastearoyl cardiolipin | 123 |
| DB02659 | CHD | Cholic Acid | 122 |
| DB01728 | PEF | 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine | 11 |
| DB09114 | PCF | Colfosceril palmitate | 2 |
| DB03317 | HEC | Ferroheme C | 1 |
| DB03619 | DXC | Deoxycholic acid | 1 |
| DB04464 | — | N-Formylmethionine | 1 |
| DB05412 | — | Talmapimod | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| HEA | HEME-A | 301 |
| CDL | CARDIOLIPIN | 156 |
| CHD | CHOLIC ACID | 144 |
| PSC | (7R,17E,20E)-4-HYDROXY-N,N,N-TRIMETHYL-9-OXO-7-[(PALMITOYLOXY)METHYL]-3,5,8-TRIOXA-4-PHOSPHAHEXACOSA-17,20-DIEN-1-AMINIUM 4-OXIDE | 131 |
| TGL | TRISTEAROYLGLYCEROL | 124 |
| PEK | (1S)-2-{[(2-AMINOETHOXY)(HYDROXY)PHOSPHORYL]OXY}-1-[(STEAROYLOXY)METHYL]ETHYL (5E,8E,11E,14E)-ICOSA-5,8,11,14-TETRAENOATE | 107 |
| DMU | DECYL-BETA-D-MALTOPYRANOSIDE | 53 |
| TRD | TRIDECANE | 26 |
| 3PE | 1,2-Distearoyl-sn-glycerophosphoethanolamine | 23 |
| LFA | EICOSANE | 22 |
| OLC | (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate | 21 |
| CDmetal | CADMIUM ION | 18 |
| HEO | HEME O | 16 |
| PEF | DI-PALMITOYL-3-SN-PHOSPHATIDYLETHANOLAMINE | 12 |
| PTY | PHOSPHATIDYLETHANOLAMINE | 11 |
| HAS | HEME-AS | 10 |
| PGV | (1R)-2-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-1-[(PALMITOYLOXY)METHYL]ETHYL (11E)-OCTADEC-11-ENOATE | 8 |
| PC1 | 1,2-DIACYL-SN-GLYCERO-3-PHOSPHOCHOLINE | 7 |
| PLX | (9R,11S)-9-({[(1S)-1-HYDROXYHEXADECYL]OXY}METHYL)-2,2-DIMETHYL-5,7,10-TRIOXA-2LAMBDA~5~-AZA-6LAMBDA~5~-PHOSPHAOCTACOSANE-6,6,11-TRIOL | 6 |
| XE | XENON | 6 |